Top-grossing drugs in systemic lupus erythematosus and lupus nephritis

Growth in the SLE segment of the marketplace will initially be driven by the release of AstraZeneca’s anifrolumab. Credit: Shutterstock + Orawan Pattarawimonchai.



  • Systemic lupus erythematosus and lupus nephritis